Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | December 2010 |
| End Date: | December 2018 |
| Contact: | Ata Sharif, MD, MBA |
| Email: | sharifs@uci.edu |
| Phone: | 949-824-9265 |
Predicting Pathological Response Within the 1st Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured With Diffuse Optical Spectroscopic Imaging
Women with Breast Cancer who do not respond to chemotherapy may undergo months of treatment
with little or no change in tumor size or overall outcome.
The Researchers have demonstrated a previously undescribed "metabolic flare" response
observed very early in neoadjuvant treatment in breast cancer patients. The research can
determine that this flare is predictive of overall therapy response and is due to both an
inflammatory reaction and cell death induced by cytotoxic therapy.
with little or no change in tumor size or overall outcome.
The Researchers have demonstrated a previously undescribed "metabolic flare" response
observed very early in neoadjuvant treatment in breast cancer patients. The research can
determine that this flare is predictive of overall therapy response and is due to both an
inflammatory reaction and cell death induced by cytotoxic therapy.
The researcher can use Diffuse Optical Spectroscopic Imaging device to measure and predict
the markers of the response in the first weeks of chemo-therapy.
The oxyhemoglobin flare response can predictive of overall pathological response to
chemotherapy in human subjects. These vascular changes can indicate the rapid transient
increase and then decrease in oxyhemoglobin concentration in the first hours and days after
therapeutic administration. The magnitude and time course of the flare response in patients
receiving cytotoxic therapy will differ between pathological responders and non-responders.
This oxyhemoglobin "flare response" can be observed In tumors where vascular dynamics are
intact.
the markers of the response in the first weeks of chemo-therapy.
The oxyhemoglobin flare response can predictive of overall pathological response to
chemotherapy in human subjects. These vascular changes can indicate the rapid transient
increase and then decrease in oxyhemoglobin concentration in the first hours and days after
therapeutic administration. The magnitude and time course of the flare response in patients
receiving cytotoxic therapy will differ between pathological responders and non-responders.
This oxyhemoglobin "flare response" can be observed In tumors where vascular dynamics are
intact.
Inclusion Criteria:
- Female, not pregnant, not breastfeeding
- greater than 21 years of age but less than 75 years of age
- will be receiving neoadjuvant chemotherapy for breast cancer as prescribed by their
oncologist
Exclusion Criteria:
- Under 21 year of age
- Female pregnant or breastfeeding
We found this trial at
3
sites
Click here to add this to my saved trials
Irvine, California 92612
Principal Investigator: Bruce Tromberg, PhD
Phone: 949-824-9265
Click here to add this to my saved trials
Click here to add this to my saved trials